Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05519085 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Study acronym: SUCCESSOR-1
StatusRecruiting
PhasePhase 3
SponsorCelgene
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 155 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Site details revised at 7 of 266 sites
  2. Study sites revised (266)v154 See this version in full on ClinicalTrials.gov ↗
  3. Study sites revised (266)v153 See this version in full on ClinicalTrials.gov ↗
  4. Study sites revised (266)v152 See this version in full on ClinicalTrials.gov ↗
  5. Study sites revised (266)v151 See this version in full on ClinicalTrials.gov ↗
Show 45 earlier versionsHide 45 earlier versions
  1. Site details revised at 1 of 266 sitesv150
  2. Study sites revised (266)v149 See this version in full on ClinicalTrials.gov ↗
  3. Site details revised at 2 of 266 sitesv148
  4. Study sites revised (266)v147 See this version in full on ClinicalTrials.gov ↗
  5. Study sites revised (266)v146 See this version in full on ClinicalTrials.gov ↗
  6. Study sites revised (266)v145 See this version in full on ClinicalTrials.gov ↗
  7. Study sites revised (266)v144 See this version in full on ClinicalTrials.gov ↗
  8. Study sites revised (266)v143 See this version in full on ClinicalTrials.gov ↗
  9. Study sites revised (266)v142 See this version in full on ClinicalTrials.gov ↗
  10. Study sites revised (266)v141 See this version in full on ClinicalTrials.gov ↗
  11. Site contacts updated at 4 of 266 sitesv140
  12. Primary completion date: Nov 3, 2025 to Jan 10, 2027 Study sites revised (266)v139 Show 1 more changeShow less
    • Study sites revised (266)

    See this version in full on ClinicalTrials.gov ↗

  13. Study sites revised (266)v138 See this version in full on ClinicalTrials.gov ↗
  14. Study sites revised (266)v137 See this version in full on ClinicalTrials.gov ↗
  15. Study sites revised (266)v136 See this version in full on ClinicalTrials.gov ↗
  16. Study sites revised (266)v135 See this version in full on ClinicalTrials.gov ↗
  17. Study sites: 265 to 266v134
  18. Study sites revised (265)v133 See this version in full on ClinicalTrials.gov ↗
  19. Study sites: 264 to 265v132
  20. Study sites revised (264)v131 See this version in full on ClinicalTrials.gov ↗
  21. Study sites: 262 to 264v130
  22. Study sites: 261 to 262v129
  23. Site details revised at 3 of 261 sitesv128
  24. Study sites revised (261)v127 See this version in full on ClinicalTrials.gov ↗
  25. Study sites revised (261)v126 See this version in full on ClinicalTrials.gov ↗
  26. Site details revised at 2 of 261 sitesv125
  27. Study sites revised (261)v124 See this version in full on ClinicalTrials.gov ↗
  28. Study sites revised (261)v123 See this version in full on ClinicalTrials.gov ↗
  29. Study sites revised (261)v122 See this version in full on ClinicalTrials.gov ↗
  30. Study sites: 260 to 261v121
  31. Study sites: 259 to 260v120
  32. Study sites: 258 to 259v119
  33. Study sites: 257 to 258v118
  34. Study sites revised (257)v117 See this version in full on ClinicalTrials.gov ↗
  35. Study sites revised (257)v116 See this version in full on ClinicalTrials.gov ↗
  36. Study sites revised (257)v115 See this version in full on ClinicalTrials.gov ↗
  37. Study sites revised (257)v114 See this version in full on ClinicalTrials.gov ↗
  38. Study sites revised (257)v113 See this version in full on ClinicalTrials.gov ↗
  39. Study sites: 250 to 257v112
  40. Study sites: 249 to 250v111
  41. Study sites: 248 to 249v110
  42. Study sites revised (248)v109 See this version in full on ClinicalTrials.gov ↗
  43. Study sites: 241 to 248v108
  44. Study sites: 239 to 241v107
  45. Study sites: 234 to 239v106
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
Trial Details
NCT Number NCT05519085
Lead Sponsor Celgene
Conditions Relapsed or Refractory Multiple Myeloma
Enrollment 810 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov